Search results for: Oncology
Filter search results
Defining Innovation in Medicines and Transforming it into Value
3 July 2013
…here, and on Shah, K.K., Mestre-Ferrandiz, J., Towse, A. and Smythe, E.N. (2013) A review of health technology appraisals: case studies in oncology. International Journal of Technology Assessment in Health Care. 29(1),…
Review of Plans for Refining Patient-Reported Outcomes Measures
19 February 2013
…the EuroQol Group’s scientific research agenda for the coming year and plans for the EQ-5D-5L approach to measuring patient-reported outcomes of care. Health technology assessment affects patients’ access to oncology…
OHE Study on Pharmaceutical R&D Costs Released
3 December 2012
…600% from the 1970s[3] to the 2000s[4]. Second, success rates for clinical development are falling as tougher therapeutic areas are tackled—e.g. neurology (Alzheimer’s), autoimmune diseases (arthritis), and oncology. Success rates…
Spotlight on OHE: Valuing Spillovers, End-of-Life Decisions and Hospital Outcomes
20 March 2012
…of life. At the Second Annual Oncology Market and Patient Access conference in January, Dr. Jorge Mestre-Ferrandiz presented preliminary results from OHE research in progress. It analyses appraisals of cancer…
Cost-Effectiveness Thresholds and Expert Elicitation: a Bridge Too Far?
29 April 2021
…not observable in clinical practice. For instance, a clinician cannot observe how changes in mortality rates in oncology might relate to changes in mortality rates in mental health. The authors…
CBO Doesn’t Capture The Real Impact of H.R. 3 on Innovation
14 September 2021
…technologies have not had the transformative effect that they have had in areas like oncology and genetic diseases. In these complex diseases, understanding of the disease and how therapeutics could…
New NICE Manual for Health Technology Evaluations: A Critical Discussion on the Most Relevant Changes (or Lack Thereof)
23 February 2022
…regimens in oncology; and clarify the meanings of absolute and proportional shortfall with examples, in early stages of the review). OHE has responded to both consultations, and in a previous…
Dementia: The R&D Landscape
1 November 2015
…observations include: R&D costs are higher for neurology and Alzheimer’s disease (AD) (as well as respiratory and oncology) than other therapy areas Higher costs are likely due to lower success…
Capturing the lived experiences of informal care in acute leukemia
20 November 2025
Share this: Download publication Samantha Nier Claud Theakston Priscila Radu David Mott Nadine Henderson Key takeaways Providing informal care to someone living with acute leukemia imposes a severe multidimensional burden,…